Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dukoral is an oral inactivated vaccine used for active immunization against disease caused by *Vibrio cholerae* serogroup O1. It contains killed whole *V. cholerae* O1 bacteria (including both Inaba and Ogawa serotypes and El Tor and Classical biotypes) and a recombinant non-toxic B subunit of the cholera toxin. The vaccine works by inducing antibodies in the intestine that target both the bacterial components and the toxin B subunit, preventing colonization of *V. cholerae* O1 on the intestinal wall as well as neutralizing the effects of cholera toxin. This immune response helps protect against infection by blocking attachment of bacteria and toxins to gut cells[1][2][5]. Dukoral is primarily indicated for travelers visiting areas where there is a risk of epidemic or endemic cholera[1][2]. It also provides some cross-protection against diarrhea caused by enterotoxigenic *Escherichia coli* (ETEC) producing heat-labile enterotoxin due to structural similarity with the cholera toxin B subunit[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholera vaccine (inactivated, oral) (Valneva).